Clinical Trials Logo

Autoimmune Encephalitis clinical trials

View clinical trials related to Autoimmune Encephalitis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05953974 Active, not recruiting - Clinical trials for Autoimmune Encephalitis

Validation of a Diagnostic Score for Encephalitis to Assess the Risk of Autoimmune Origin

Val-Dia score
Start date: February 1, 2023
Phase:
Study type: Observational

The investigators wish to test a diagnostic risk score for autoimmune encephalitis in case of encephalitis, previously validated by two American teams, in a retrospective analysis, according to the clinical and paraclinical data available in our database of the Reference Centre for Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of Professor Honnorat for patients with NMDAr, anti LGi1, anti CASPR2, anti GABAbr and anti GAD antibodies.

NCT ID: NCT05728931 Active, not recruiting - Clinical trials for Autoimmune Encephalitis

New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes

DeNobio
Start date: January 15, 2022
Phase:
Study type: Observational

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients. The investigators will use this project to better characterize AE and PNS patients to identify new diagnostic and prognostic biomarkers and develop new diagnostic tools.